Advanced Biomed Inc. Unveils A+PerfusC™ – A Cutting-Edge 3D Cell Culture Platform for Precision Medicine and Drug Development

Written by Emily J. Thompson, Senior Investment Analyst

Source: Newsfilter

Updated: Sep 19 2025

0mins

ADVB-2.93%

Should l Buy ADVB?

Source: Newsfilter

Launch of A+PerfusC™ System: Advanced Biomed Inc. has introduced the A+PerfusC™ system, a compact 3D cell culture incubator that mimics human physiological conditions, allowing for up to 12 days of continuous, hands-free culture to enhance cell viability and drug response predictability.
Market Potential and Applications: The global 3D cell culture market is projected to grow significantly, with applications for the A+PerfusC™ system including personalized oncology research, in vitro drug screening, and regenerative medicine, as the company aims to integrate AI-driven analytics for tumor profiling and cell therapy advancements.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy ADVB?" and start using high-conviction signals backed by rigorous historical data.

ADVB

$0.2319+Infinity%1D

Analyst Views on ADVB

About ADVB

Advanced Biomed Inc. is a holding company that operates, through its subsidiary, Advanced Biomed Inc. (Taiwan). The Company is engaged in the provision of assay products and services for cancer patients. These services include early screening and detection, diagnosis and staging, and treatment of cancer through the detection of circulating tumor cells and related tumor markers. It has developed a microfluidic technology platform to integrate research and development, design, and manufacture of biochips and microfluidic chips. The platform combines its patented chip technology and will enable localized operations of a variety of microfluidic chips, biosensors made by semiconductor fabrication technology, and integrated application patented technology. The Company offers devices, such as A+Pre, AC-1000, A+CellScan, and A+SCDrop, and three corresponding microfluidic biochips, A+Pre-Chip and AC-1000 CTC Enrichment Chip and A+CellScan Chip.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Advanced Biomed Sells Hong Kong Subsidiary for $23,000

Dec 30 2025Globenewswire

Asset Divestiture: Advanced Biomed entered into an agreement on December 23, 2025, to sell its wholly-owned subsidiary Advanced Biomed (HK) Limited for $23,000, aiming to address evolving regulatory requirements in China regarding clinical trials and to centralize resources for trials in Taiwan.
Intellectual Property Transfer: All intellectual property owned by the Hong Kong subsidiary, including that of its wholly-owned subsidiary Shanghai Sglcell Biotech Co., Ltd., was transferred to the buyer, which will help mitigate legal risks in future product development.
Strategic Realignment: The CEO stated that this divestiture is intended to accelerate product development and commercialization, with all clinical trials now centralized in Taiwan, thereby enhancing operational efficiency and optimizing resource allocation.
Market Expansion Plans: Advanced Biomed is developing a microfluidic platform in Taiwan with future global expansion plans; although this sale may impact short-term financial performance, it is expected to enhance the company's competitiveness in the precision medicine sector in the long run.

Advanced Biomed Sells Hong Kong Subsidiary for $23,000

Dec 30 2025Newsfilter

Asset Divestiture: Advanced Biomed entered into an agreement on December 23, 2025, to sell its wholly-owned subsidiary, Advanced Biomed (HK) Limited, for $23,000, aiming to address evolving regulatory requirements for clinical trials and centralize operations through its Taiwan subsidiary.
Intellectual Property Transfer: All intellectual property owned by the Hong Kong subsidiary, including that of its wholly-owned Shanghai subsidiary, was transferred to the buyer, which will streamline processes in future product development and commercialization efforts.
Strategic Realignment: The CEO indicated that this divestiture is part of a strategic realignment to accelerate the development and commercialization of products and solutions, focusing resources on the Taiwan market to adapt to changing market conditions.
Future Outlook: By centralizing clinical trials in its Taiwan subsidiary, Advanced Biomed aims to enhance its competitiveness in the precision medicine sector and lay the groundwork for future global expansion.

2025 IPO Successes and Failures: Figma, Bullish, and Klarna Drive $31 Billion Revival

Sep 29 2025TipRanks

Strong IPO Activity in 2025: As of late September 2025, 254 companies have gone public on the NYSE and Nasdaq, surpassing the total for 2024 and 2023, with a significant increase in activity during the summer months, particularly in technology and financial technology sectors.
Diverse Performance Among IPOs: While some companies like Reddit and CoreWeave have seen substantial gains, others such as Figma and Firefly Aerospace have experienced significant declines, indicating a selective investor sentiment in the IPO market.